ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
June 10, 2021Vertex Pharmaceuticals Incorporated today announced the FDA approved expanded use of Trikafta to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance -
Australian TGA approves Vertex’s Trikafta for cystic fibrosis treatment
March 26, 2021The Australian Therapeutic Goods Administration (TGA) has approved the use of Vertex Pharmaceutical’s Trikafta (elexacaftor, tezacaftor, ivacaftor and ivacaftor) for people with cystic fibrosis (CF) aged 12 years and above.
Pharma Sources Insight January 2025
